Ginkgo Bioworks Stock News

Although the innovation space may be on the verge of a broader correction, certain ideas may pop higher, which brings us to Cathie Wood stocks to make you rich. One of the most respected names on Wall

Growth stocks are an important element of a well-balanced portfolio. Ginkgo Bioworks and Harmony Biosciences are two risky growth plays that could deliver stellar returns over the long term.

Shockwave Medical just got a boost from a Medicare decision on one of its products. Bio-Techne is benefiting from increased cell and gene therapy revenue.

Ginkgo Bioworks and Pfizer announced a new RNA therapeutics collaboration today. In response, Ginkgo Bioworks' stock jumped by double digits in early-morning trading Wednesday.

Smart investors are looking for ways to put their money to work well. NextEra Energy Partners cut its expectations for distribution growth.

Ginkgo Bioworks (NYSE: DNA ) stock jumped almost 14% overnight after it signed a collaboration agreement with Pfizer (NYSE: PFE ). The deal gives Ginkgo upfront cash and could eventually be worth $33

Cathie Wood stocks have captivated investors for years now. Wood is a popular money manager because her investing style isn't so different from many small retail investors.

Consensus price targets from Wall Street analysts suggest a pair of healthcare stocks can more than double your money. Hims & Hers Health runs an increasingly popular niche telehealth platform where p

Biotech has long seemed to move slower than its fellow tech fields due to the complexity of biological systems and the difficulty of drug regulations. However, that precedent is set to change thanks t

Alphabet and Ginkgo Bioworks just inked a five-year AI deal. It won't solve any of Ginkgo's major issues, but it could help at the margin.

Pursuing undervalued Cathie Wood stocks radiates a magnetic allure for investors aiming for a hefty financial breakthrough. The stocks favored by Wood are risky but grounded in foresight, offering tre

Cathie Wood likes to buy innovative and disruptive companies. She's been buying both Intellia Therapeutics and Ginkgo Bioworks recently.

The biotech announced not one, but two partnerships in the past few days. One was with a top name in the tech sector.

Jason Kelly, Ginkgo Bioworks CEO, joins 'Closing Bell Overtime' to talk partnering with Google Cloud, its AI offerings and more.

Viking Global Investors, the investment firm founded by Andreas Halvorsen (Trades, Portfolio) in 1999, disclosed earlier this week it boosted its stake in Inhibrx Inc. ( INBX , Financial) by 7.71% fol